ClariTrial | Search Clinical Trials

Explore/cancer oncology

Status

Phase

Pre-filtered to show active, later-stage trials with the strongest clinical signal.

6,321 results for “cancer oncology” · Recruiting · Phase 3 · Phase 2

Page 1 of 422

Recruiting

Time-limited Triplet Combination of Pirtobrutinib, Venetoclax, and Obinutuzumab for Patients With Treatment-naïve Chronic Lymphocytic Leukemia (CLL) or Richter Transformation (RT)

Phase 2Leukemia

PirtobrutinibObinutuzumabVenetoclax+2 more

M.D. Anderson Cancer Center60 participants1 site · United StatesCompletes Apr 2028

Compare CT.gov Full analysis →

Recruiting

Psilocybin Therapy in Advanced Cancer

Phase 2Phase 3Advanced Cancer

Psilocybin 25 mgsNiacin 100mgPsychotherapy

NYU Langone Health200 participants2 sites · United StatesCompletes Jan 2027

Compare CT.gov Full analysis →

Recruiting

Study of SHR-A1811 Combined With Pyrotinib and Bevacizumab in Advanced Breast Cancer With Brain Metastasis

Phase 1Phase 2Breast Cancer MetastaticBreast Cancer Brain Metastases

SHR-A1811BevacizumabPyrotinib

Fudan University74 participants1 site · ChinaCompletes Aug 2026

Compare CT.gov Full analysis →

Recruiting

Zanubrutinib With Obinutuzumab in Untreated Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Phase 2Chronic Lymphocytic LeukemiaSmall Lymphocytic Lymphoma

Zanubrutinib Oral ProductObinutuzumab

PETHEMA Foundation106 participants19 sites · SpainCompletes May 2032

Compare CT.gov Full analysis →

Recruiting

A Study of Ifinatamab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01D/LIGHTBEAM-U01)

Phase 1Phase 2Malignant Neoplasm

Ifinatamab Deruxtecan

Merck Sharp & Dohme LLC134 participants25 sites · United States, Belgium, DenmarkCompletes Aug 2031

Compare CT.gov Full analysis →

Recruiting

Pembrolizumab for Advanced NSCLC and PS 2-3

Phase 2Non-Small Cell Lung Cancer (NSCLC)

Pembrolizumab

Icahn School of Medicine at Mount Sinai45 participants1 site · United StatesCompletes May 2027

Compare CT.gov Full analysis →

Recruiting

Anlotinib Plus Whole-Brain Radiotherapy for Brain Metastases in SCLC Patients.

Phase 3Whole-Brain Radiotherapy

AnlotinibWhole-brain Radiotherapy

Cancer Institute and Hospital, Chinese Academy of Medical Sciences134 participants1 site · ChinaCompletes Aug 2027

Compare CT.gov Full analysis →

Recruiting

Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell Lymphoma

Phase 2Non-Hodgkin's LymphomaDiffuse Large B-Cell LymphomaDLBCL

DA-EPOCHRituximabCHOP+1 more

National Cancer Institute (NCI)132 participants1 site · United StatesCompletes May 2027

Compare CT.gov Full analysis →

Recruiting

Clinical Study of Second-line Treatment in Advanced Colorectal Cancer With Chemotherapy With Bevacizumab or Cetuximab

Phase 2Colorectal Cancer Metastatic

irinotecan liposome (II)fluorouracilcetuximab+2 more

Second Affiliated Hospital, Zhejiang University, School of Medicine100 participants1 site · ChinaCompletes Apr 2026

Compare CT.gov Full analysis →

Recruiting

A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations

Phase 1Phase 2Breast CancerEndometrial CancerOvarian Cancer

TER-2013Fulvestrant injection

Terremoto Biosciences Inc.205 participants18 sites · United States, Puerto RicoCompletes Dec 2028

Compare CT.gov Full analysis →

Recruiting

Intensified Treatments for Patients With Locally Advanced Nasopharyngeal Carcinoma With Detectable EBV DNA After One Cycle GP Regime Neoadjuvant Chemotherapy

Phase 3Nasopharyngeal Carcinoma

CamrelizumabNimotuzumabneoadjuvant chemotherapy and CCRT

Fudan University459 participants1 site · ChinaCompletes Jan 2025

Compare CT.gov Full analysis →

Recruiting

Chemotherapy Combined With Adebrelimab and Apatinib as the Perioperative Treatment in Patients With Biliary Tract Cancer

Phase 2Resectable Intrahepatic Cholangiocarcinoma With High Risk of Recurrence

Adebrelimab, Apatinib, Gemcitabine, cisplatin

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University40 participants1 site · ChinaCompletes Mar 2027

Compare CT.gov Full analysis →

Recruiting

Tirilizumab with Albumin-bound Paclitaxel and Cisplatin for Locally Advanced Resectable Oral Squamous Cell Carcinoma

Phase 2Locally Advanced Head and Neck Squamous Cell Carcinoma

tirilizumab with albumin-bound paclitaxel and cisplatinsurgery

Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University116 participants1 site · ChinaCompletes Jun 2025

Compare CT.gov Full analysis →

Recruiting

SCRT Followed by AK112 in pMMR/MSS Mid-low Rectal Cancer

Phase 2Rectal CancerRadiationAK112

radiotherapyIvonescimab (20mg/kg Q3W)Non-operative Management+1 more

Zhejiang Cancer Hospital30 participants1 site · ChinaCompletes Mar 2027

Compare CT.gov Full analysis →

Recruiting

Tinzaparin And Biomarkers After Neoadjuvant Treatment of Ovarian Cancer

Phase 2Epithelial Ovarian Cancer

Tinzaparin Injectable Solution

University Hospital, Linkoeping40 participants8 sites · SwedenCompletes Dec 2027

Compare CT.gov Full analysis →

1–15 of 6,321

Explore/cancer oncology

Status

Phase

Pre-filtered to show active, later-stage trials with the strongest clinical signal.

6,321 results for “cancer oncology” · Recruiting · Phase 3 · Phase 2

Page 1 of 422

Recruiting

Time-limited Triplet Combination of Pirtobrutinib, Venetoclax, and Obinutuzumab for Patients With Treatment-naïve Chronic Lymphocytic Leukemia (CLL) or Richter Transformation (RT)

Phase 2Leukemia

PirtobrutinibObinutuzumabVenetoclax+2 more

M.D. Anderson Cancer Center60 participants1 site · United StatesCompletes Apr 2028

Compare CT.gov Full analysis →

Recruiting

Psilocybin Therapy in Advanced Cancer

Phase 2Phase 3Advanced Cancer

Psilocybin 25 mgsNiacin 100mgPsychotherapy

NYU Langone Health200 participants2 sites · United StatesCompletes Jan 2027

Compare CT.gov Full analysis →

Recruiting

Study of SHR-A1811 Combined With Pyrotinib and Bevacizumab in Advanced Breast Cancer With Brain Metastasis

Phase 1Phase 2Breast Cancer MetastaticBreast Cancer Brain Metastases

SHR-A1811BevacizumabPyrotinib

Fudan University74 participants1 site · ChinaCompletes Aug 2026

Compare CT.gov Full analysis →

Recruiting

Zanubrutinib With Obinutuzumab in Untreated Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Phase 2Chronic Lymphocytic LeukemiaSmall Lymphocytic Lymphoma

Zanubrutinib Oral ProductObinutuzumab

PETHEMA Foundation106 participants19 sites · SpainCompletes May 2032

Compare CT.gov Full analysis →

Recruiting

A Study of Ifinatamab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01D/LIGHTBEAM-U01)

Phase 1Phase 2Malignant Neoplasm

Ifinatamab Deruxtecan

Merck Sharp & Dohme LLC134 participants25 sites · United States, Belgium, DenmarkCompletes Aug 2031

Compare CT.gov Full analysis →

Recruiting

Pembrolizumab for Advanced NSCLC and PS 2-3

Phase 2Non-Small Cell Lung Cancer (NSCLC)

Pembrolizumab

Icahn School of Medicine at Mount Sinai45 participants1 site · United StatesCompletes May 2027

Compare CT.gov Full analysis →

Recruiting

Anlotinib Plus Whole-Brain Radiotherapy for Brain Metastases in SCLC Patients.

Phase 3Whole-Brain Radiotherapy

AnlotinibWhole-brain Radiotherapy

Cancer Institute and Hospital, Chinese Academy of Medical Sciences134 participants1 site · ChinaCompletes Aug 2027

Compare CT.gov Full analysis →

Recruiting

Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell Lymphoma

Phase 2Non-Hodgkin's LymphomaDiffuse Large B-Cell LymphomaDLBCL

DA-EPOCHRituximabCHOP+1 more

National Cancer Institute (NCI)132 participants1 site · United StatesCompletes May 2027

Compare CT.gov Full analysis →

Recruiting

Clinical Study of Second-line Treatment in Advanced Colorectal Cancer With Chemotherapy With Bevacizumab or Cetuximab

Phase 2Colorectal Cancer Metastatic

irinotecan liposome (II)fluorouracilcetuximab+2 more

Second Affiliated Hospital, Zhejiang University, School of Medicine100 participants1 site · ChinaCompletes Apr 2026

Compare CT.gov Full analysis →

Recruiting

A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations

Phase 1Phase 2Breast CancerEndometrial CancerOvarian Cancer

TER-2013Fulvestrant injection

Terremoto Biosciences Inc.205 participants18 sites · United States, Puerto RicoCompletes Dec 2028

Compare CT.gov Full analysis →

Recruiting

Intensified Treatments for Patients With Locally Advanced Nasopharyngeal Carcinoma With Detectable EBV DNA After One Cycle GP Regime Neoadjuvant Chemotherapy

Phase 3Nasopharyngeal Carcinoma

CamrelizumabNimotuzumabneoadjuvant chemotherapy and CCRT

Fudan University459 participants1 site · ChinaCompletes Jan 2025

Compare CT.gov Full analysis →

Recruiting

Chemotherapy Combined With Adebrelimab and Apatinib as the Perioperative Treatment in Patients With Biliary Tract Cancer

Phase 2Resectable Intrahepatic Cholangiocarcinoma With High Risk of Recurrence

Adebrelimab, Apatinib, Gemcitabine, cisplatin

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University40 participants1 site · ChinaCompletes Mar 2027

Compare CT.gov Full analysis →

Recruiting

Tirilizumab with Albumin-bound Paclitaxel and Cisplatin for Locally Advanced Resectable Oral Squamous Cell Carcinoma

Phase 2Locally Advanced Head and Neck Squamous Cell Carcinoma

tirilizumab with albumin-bound paclitaxel and cisplatinsurgery

Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University116 participants1 site · ChinaCompletes Jun 2025

Compare CT.gov Full analysis →

Recruiting

SCRT Followed by AK112 in pMMR/MSS Mid-low Rectal Cancer

Phase 2Rectal CancerRadiationAK112

radiotherapyIvonescimab (20mg/kg Q3W)Non-operative Management+1 more

Zhejiang Cancer Hospital30 participants1 site · ChinaCompletes Mar 2027

Compare CT.gov Full analysis →

Recruiting

Tinzaparin And Biomarkers After Neoadjuvant Treatment of Ovarian Cancer

Phase 2Epithelial Ovarian Cancer

Tinzaparin Injectable Solution

University Hospital, Linkoeping40 participants8 sites · SwedenCompletes Dec 2027

Compare CT.gov Full analysis →

1–15 of 6,321